

Clinical Breakthroughs in Pain Therapy Unveiled Next Month at Pain Therapeutics 2016

Pfizer, Regeneron, Imperial College London, Novartis and MSD USA Showcase Clinical Breakthroughs in 5 Exclusive Presentations

LONDON, ENGLAND, UNITED KINGDOM, April 25, 2016 /EINPresswire.com/ -- As well as being supported by leading scientific experts in the area of neuropathic pain and featuring a panel of senior representatives from international pharmaceutical organisations, SMI's 16th annual [Pain Therapeutics](#) conference taking place on 23rd & 24th May in Central London, will include a dedicated spotlight on the latest clinical breakthroughs with FIVE exclusive [presentations](#) on key evolving therapies.

1. Voltage Gated Sodium Channels: New Pain Therapies Revealed

Aoibhinn McDonnell, Clinician, Director, Pfizer

Delegates will receive new updates on the pre-clinical and clinical development of selective sodium channel blockers with results from the assessment of PF-05089771 in painful diabetic neuropathy.

2. Treatment of moderate to severe chronic pain



I am looking forward to hearing about new molecules in pre-clinical and clinical stages

Novartis

Catherine Stehman-Breen, VP Clinical Sciences, Regeneron Pharmaceuticals Inc

Regeneron discuss the epidemiology of moderate to severe chronic pain and explore emerging new treatment options.

3. Small Fibre Neuropathy and Channelopathy: From Pain Relief to Disease Modification

Praveen Anand, Professor of Neurology, Imperial College London

Imperial College London explore advanced diagnostic techniques through case studies on clinical translation success in Phase II trials; and capsaicin 8% patch Qutenza for pain relief and disease modification.

4. A Novel Treatment Option for Neuropathic Pain

Shaloo Pandhi, Global Program Medical Director, Novartis

Evidence of safety and analgesic action of EAM410 has been demonstrated in robust pre-clinical and classical clinical models of peripheral neuropathic pain. Novartis discuss the next steps in clinical development.

5. Translational Assays: Supporting a Small Molecule Nav1.7 Inhibitor Program

Andrea Houghton, Executive Director, MSD, USA



Attendees will learn how novel assays in vivo assays are used in the development of a small molecule Nav1.7 inhibitor. MSD answer the question, how can these assays be used in a phase 1 program?

Additional speakers on the programme include GSK, Glenmark Pharmaceuticals, University College London, Reckitt Benckiser, Nektar Therapeutics, Zeotis and Grunenthal GmbH.

Further details including a full line-up and conference agenda is available at www.pain-therapeutics.co.uk

16 Annual Conference: Pain Therapeutics 2016

23rd - 24th May 2016

Holiday Inn Kensington Forum, London UK

Sponsored by: Cellectricon AB, Centre for Human Drug Research, MD Biosciences and PRA Health Services

---end---

About SMi Group:

Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the worlds most forward thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at <http://www.smi-online.co.uk>

Teri Arri
SMi Group
+442078276000
email us here

This press release can be viewed online at: <http://www.einpresswire.com>

Disclaimer: If you have any questions regarding information in this press release please contact the company listed in the press release. Please do not contact EIN Presswire. We will be unable to assist you with your inquiry. EIN Presswire disclaims any content contained in these releases.

© 1995-2016 IPD Group, Inc. All Right Reserved.